A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer by Heinemann, Volker et al.
European Journal of Cancer 67 (2016) 11e20Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.ejcancer .comOriginal ResearchA study-level meta-analysis of efficacy data from
head-to-head first-line trials of epidermal growth factor
receptor inhibitors versus bevacizumab in patients with
RAS wild-type metastatic colorectal cancerVolker Heinemann a,*, Fernando Rivera b, Bert H. O’Neil c,
Sebastian Stintzing a, Reija Koukakis d, Jan-Henrik Terwey e,
Jean-Yves Douillard fa Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Grosshadern,
Marchioninistr. 15, D-81377, Munich, Germany
b Department of Medical Oncology, Hospital Universitario Marque´s de Valdecilla, Av. de Valdecilla, 39008, Santander, Spain
c Department of Oncology, Indiana University Simon Cancer Center, 535 Barnhill Drive, Indianapolis, IN, 46202, USA
d Biostatistics, Amgen Ltd, 1 Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH, UK
e Medical Development, Amgen Switzerland AG, Dammstrasse 23, 6301, Zug, Switzerland
f Department of Medical Oncology, Institut de Cance´rologie de l’Ouest (ICO) Rene´ Gauducheau, 44805, St Herblain, FranceReceived 14 July 2016; accepted 17 July 2016
Available online 1 September 2016KEYWORDS
Bevacizumab;
Cetuximab;
Panitumumab;
Meta-analysis;
Survival;
Progression-free
survival* Corresponding author. Fax: þ49 (0)8
E-mail addresses: Volker.Heineman
Sebastian.Stintzing@med.uni-muenche
jean-yves.douillard@esmo.org (J.-Y. Do
http://dx.doi.org/10.1016/j.ejca.2016.07.0
0959-8049/ª 2016 The Authors. Pub
creativecommons.org/licenses/by-nc-nd/Abstract Background: Head-to-head trials comparing first-line epidermal growth factor
receptor inhibitor (EGFRI) versus vascular endothelial growth factor inhibitor (bevacizumab)
therapy yielded differing results, and debate remains over optimal first-line therapy for
patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC).
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V. Heinemann et al. / European Journal of Cancer 67 (2016) 11e2012Results: Three trials comprising data from 1096 patients with RASWT mCRC were included.
OS (hazard ratio [HR]: 0.80 [95% confidence interval: 0.68e0.93]), ORR (odds ratio [OR]:
0.57) and ETS (OR: 0.48) favoured EGFRIs plus chemotherapy versus bevacizumab plus
chemotherapy. PFS (HR: 0.98) and resections (OR: 0.93) were similar between treatments.
For patients with KRAS exon 2 WT/‘other’ RASmutant mCRC the OS HR was 0.70. A safety
meta-analysis was not possible due to a lack of data; in the individual studies, skin toxicities
and hypomagnesaemia were more common with EGFRIs, nausea and hypertension were
more common with bevacizumab.
Conclusions: This meta-analysis supports a potential benefit for first-line EGFRI plus chemo-
therapy versus bevacizumab plus chemotherapy with respect to OS, ORR and ETS in patients
with RAS WT mCRC. A patient-level meta-analysis is awaited.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Irinotecan- or oxaliplatin-based chemotherapy combined
with epidermal growth factor receptor inhibitors (EGF-
RIs: cetuximab and panitumumab) or the vascular endo-
thelial growth factor inhibitor (VEGFI) bevacizumab are
standard first-line treatments for patients with metastatic
colorectal cancer (mCRC) [1e3]. The efficacyofFOLFIRI
and FOLFOX appears similar in these patients, although
toxicity profiles differ [4]. Choice of chemotherapy back-
bone appears to have no significant impact when given
alongside biological therapy in the first-line setting [5e7];
therefore, the key treatment choice is which targeted agent
togiveupfront.Evaluationofmutations in exons 2, 3 and4
of KRAS and NRAS (extended RAS analysis) improves
identification of patients unlikely to respond to EGFRIs
compared with evaluating KRAS exon 2 alone and is
essential before beginning EGFRI therapy [8,9]. The
importance of evaluating tumour RAS status ahead of
bevacizumab treatment is less clear [10e12].
Data from three head-to-head first-line trials have
been reported evaluating EGFRIs versus bevacizumab in
patients with mCRC [13e17]. In general, progression-
free survival (PFS) was similar between treatments, but
two of the three trials indicated an overall survival (OS)
benefit for EGFRIs in patients with RAS wild-type (WT)
mCRC [14,17]. In contrast, the largest trial reported no
PFS or OS differences [15]. Debate, therefore, remains
over optimal first-line therapy for patients with RASWT
mCRC and the potential impact of treatment sequencing
on long-term survival. The aim of this study-level meta-
analysis was to determine the relative efficacy of first-line
treatment with EGFRIs þ chemotherapy versus
bevacizumab þ chemotherapy, specifically in patients
with RAS WT mCRC.
2. Methods
2.1. Search strategy and selection criteria
A PubMed search was conducted in July 2015 including
the search terms ‘EGFR’ or ‘VEGF’ and ‘panitumumab/cetuximab/bevacizumab’ and ‘metastatic CRC’ and ‘trial
or study’. From the results obtained, first-line trials
comparing EGFRIs þ chemotherapy versus VEGFI
(bevacizumab) þ chemotherapy were manually selected.
Once relevant trials were identified, key congresses
(ASCO 2014, ESMO 2014, ECC 2015) in the prior 2
years were manually searched for updated data. More
up-to-date, unpublished data on file were included,
where available.
2.2. Objectives
The primary objective of this meta-analysis was to
estimate the treatment effect on OS of first-line
EGFRIs þ chemotherapy versus first-line
bevacizumab þ chemotherapy in patients with RAS
WT mCRC. Secondary objectives included estimation
of the treatment effect on PFS, objective response rate
(ORR), resection rates and safety (grade 3/4 adverse
events [AEs]). Early tumour shrinkage (ETS) of 20%
at week 6 or 8 was an exploratory end-point.
2.3. Analyses
Data for patients with RAS WT mCRC were extracted
into SAS datasets. Where investigator assessed and
independent, centrally reviewed response data were
available, the latter were included in the analysis. The
RAS WT population included all patients without
detectable mutations in KRAS or NRAS exons 2, 3 or 4.
The primary analysis set was based on the RAS WT
population, assumed that FOLFOX and FOLFIRI were
equivalent and used both stratified and unstratified
hazard ratios (HRs), where data were available.
Random- and fixed-effects models were used for the
primary analysis. Sensitivity analyses were conducted to
evaluate the primary and secondary end-points using
FOLFOX only and FOLFIRI only as the backbone
chemotherapy.
For dichotomous data, the number of patients with
the outcome of interest was collected by treatment
group. Rates and odds ratios (ORs), and relative
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(CIs) and p-values, were extracted where available, or
calculated (where possible). For continuous outcomes,
medians, range, with corresponding 95% CIs and
p-values were collected by treatment group, where
available, or calculated (where possible). Time-to-event
outcomes (OS and PFS) were reported using HRs with
corresponding 95% CIs and p-values. Meta-analysis
techniques, including fixed-effects modelling (uncondi-
tional maximum likelihood method) and random-effects
modelling (DerSimonian and Laird modelling methods)
[18], were used to pool study-level trial data using the
inverse-variance of each study as the weight. Meta-
analysis of trial HRs or ORs (dependent on end-point)
were performed using SAS version 9.2 or higher.
Heterogeneity was statistically assessed using the I2
statistic. Baseline demographics/disease characteristics
were indirectly compared across trials and key safety/
tolerability data summarised for each study. The most
recently reported data for each trial were included in the
analyses; data for the KRAS exon 2 WT population
were included for completeness where corresponding
data for the RAS WT population were not available.
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.3. Results
Three first-line, head-to-head mCRC trials were included
in the meta-analysis (one trial had only been published in
abstract form, but was included in a meta-analysis
identified on PubMed). These were CALGB/SWOG
80405 (phase III trial comparing bevacizumab or
cetuximab þ FOLFOX or FOLFIRI [NCT00265850])
[13,15], FIRE-3 (phase III trial comparing
cetuximabþFOLFIRI versus bevacizumabþFOLFIRI
[NCT00433927]) [16,19] and PEAK (phase II trial
comparing panitumumab þ FOLFOX versus
bevacizumab þ FOLFOX [NCT00819780]) [17,20].
These studies included a total of 1096 patients with
RAS WT mCRC. This comprised 526 [15], 400 [16] and
170 [20] patients from CALGB/SWOG 80405, FIRE-3
and PEAK, which represented 46%, 68% and 60% of
the study intent-to-treat populations, respectively.
Baseline data were reported for the RAS assessable/
evaluable populations in CALGB [15] and FIRE-3 [14]
and for the RAS WT population in PEAK [17]. In
general (where reported), study populations appeared
similar with respect to sex, age, Eastern Cooperative
Oncology Group performance status, prior adjuvant
therapy and number of metastatic sites (Table 1).
Primary colon cancer was more common in PEAK than
FIRE-3 (71% and 59% [not reported in CALGB]),
whereas liver-only metastases were present in 34%, 25%
and 27% of patients in CALGB, FIRE-3 and PEAK,
respectively. For the reader’s reference, a summary of
key efficacy data for the RAS WT population from each
trial is included in Table 2.
Table 2
Summary of key efficacy data from clinical studies comparing first-line epidermal growth factor receptor inhibitors þ chemotherapy versus first-line bevacizumab þ chemotherapy and reporting results
for patients with RAS wild-type metastatic colorectal cancer.
Primary
end-point
RAS wild-type population [15,16,20]
n Median OS,
months
Median PFS,
months
ORR (%) ETSa (%) Median DpRb (%)
CALGB/SWOG 80405 OS
Cetuximab þ chemotherapyc 270 32.0 11.4 69 NR NR
Bevacizumab þ chemotherapyc 256 31.2 11.3 54 NR NR
HR or OR (95% CI) HR: 0.9 (0.7, 1.1);
p Z 0.40
HR: 1.1 (0.9, 1.3);
p Z 0.31
NR; p < 0.01 NR NR
FIRE-3 ORR
Cetuximab þ FOLFIRI 199 33.1 10.3 72 68 49
Bevacizumab þ FOLFIRI 201 25.0 10.2 56 49 32
HR or OR (95% CI) HR: 0.70 (0.54, 0.90);
p Z 0.0059
HR: 0.97 (0.78, 1.20);
p Z 0.77
OR: 2.01 (1.27, 3.19);
p Z 0.003
OR: 2.22 (1.41, 3.47);
p Z 0.0005
NR; p < 0.0001
PEAK PFS
Panitumumab þ FOLFOX 88 36.9 12.8 65 75 65
Bevacizumab þ FOLFOX 82 28.9 10.1 60 62 46
HR or OR (95% CI) HR: 0.76 (0.53, 1.11);
p Z 0.15
HR: 0.68 (0.48, 0.96);
p Z 0.029
OR: 1.12 (0.56, 2.22);
p Z 0.86
OR: 1.67 (NR);
p Z 0.21
p Z 0.0018
Abbreviations: CI, confidence intervals; DpR, depth of response; ETS, early tumour shrinkage; HR, hazard ratio; NR, not reported;OR, odds ratio; ORR, objective response rate; OS, overall survival;
PFS, progression-free survival.
a Proportion of patients with ETS of 20% at week 6 or 8.
b Percentage of maximal tumour shrinkage at nadir versus baseline.
c Chemotherapy included FOLFOX for w75% of patients and FOLFIRI for w25% of patients.
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Meta-analysis results for OS in the RAS WT population
favoured EGFRIs þ chemotherapy versus
bevacizumab þ chemotherapy (HR: 0.80 [95% CI: 0.68,
0.93]; Fig. 1A). For patients withKRAS exon 2WT/’other’
RAS mutant mCRC, the OS HR (95% CI) was 0.70 (0.50,
0.99) (Supplemental Fig. A1; includes previously
unpublishedFIRE-3 data). In the PFS analysis ofRASWT
patients, theHR(95%CI) for theEGFRIsþ chemotherapy
versus bevacizumab þ chemotherapy was 0.98 (0.86,
1.12), suggesting no difference between treatments
(Fig. 1B). For ORR, the OR favoured the EGFRIs
(0.57 [95% CI: 0.42, 0.76]; Fig. 2A) and the relative
difference (EGFRIs þ chemotherapy [%] minusStudy
CALGB (N=526)
FIRE-3 (N=400)
PEAK (N=170)
Total (Fixed)
Total (Random)
Favours EGFRI
+chemotherapy
Favours bevacizumab
+chemotherapy
0.1 1 1
Study
CALGB (N=526)
FIRE-3 (N=400)
PEAK (N=170)
Total (Fixed)
Total (Random)
Favours EGFRI
+chemotherapy
Favours bevacizumab
+chemotherapy
0.1 1 1
A
B
Fig. 1. Forest plots showing meta-analysis results for (A) overall su
Weight is relative weight (%) from the fixed-effect model. p-value is tw
receptor inhibitor; HR, hazard ratio; N, total study size, n, total numb
evaluable in the bevacizumab arm.bevacizumab þ chemotherapy [%]) was 13.1 (95%
CI:19.7, 6.6) (Fig. 2B).
Sensitivity analyses of OS and PFS by chemotherapy
backbone are shown in Supplemental Figs. A2 and A3.
ETS data for the RAS WT population were available
from FIRE-3 (ETS at week 6 reported) and PEAK (ETS
at week 8 reported). ETS occurred at a significantly
higher rate in EGFRI-treated patients (OR: 0.48 [95%
CI: 0.33, 0.71]; Supplemental Fig. A4A). The relative
difference in ETS rates was 17.0 (95% CI: 25.4, 8.5;
Supplemental Fig. A4B).
At the time of analysis, resection data for
the RAS WT population were only available from
FIRE-3 and PEAK (Supplemental Fig. A5; includes
previously unpublished FIRE-3 data). The ORn/n1/n2 HR [95% CI] p-value Weight
526/270/256 0.90 [0.70, 1.10] 0.4000 46.4
0.70 [0.54, 0.90] 0.0059 36.3
170/88/82 0.76 [0.53, 1.11] 0.1500 17.3
0.80 [0.68, 0.93] 0.0038 100.0
0.79 [0.67, 0.94] 0.0061
400/199/201
Heterogeneity: Chi2=2.23, df=2, (p=0.33), I2=10%, Tau2=0
0
n/n1/n2 HR [95% CI] p-value Weight
526/270/256 1.10 [0.90, 1.30] 0.3100 49.7
0.97 [0.78, 1.20] 0.7700 36.3
170/88/82 0.68 [0.48, 0.96] 0.0290 14.0
0.98 [0.86, 1.12] 0.7900 100.0
0.93 [0.74, 1.18] 0.5733
400/199/201
Heterogeneity: Chi2=5.8, df=2, (p=0.06), I2=65%, Tau2=0.03
0
rvival, (B) progression-free survival (RAS wild-type population).
o sided. CI, confidence interval; EGFRI, epidermal growth factor
er evaluable; n1, number evaluable in the EGFRI arm; n2, number
Favours EGFRI
+chemotherapy
Favours bevacizumab
+chemotherapy Heterogeneity: Chi2=1.79, df=2, (p=0.41), I2=0%, Tau2=0
-40 -20 0 20 40
330/157/173
319/159/160 -14.8 [-25.4,-4.2] 0.0061 38.5
-15.9 [-26.1, -5.7] 0.0022 41.3
169/88/81 -4.3 [-18.9, 10.3] 0.5635 20.2
-13.1 [-19.7, -6.6] <0.0001 100.0
-13.1 [-19.7, -6.6] <0.0001
n/n1/n2 RD [95% CI] p-value Weight
Study
CALGB (N=526)
FIRE-3 (N=400)
PEAK (N=170)
Total (Fixed)
Total (Random)
A
B
Study
CALGB (N=526)
FIRE-3 (N=400)
PEAK (N=170)
Total (Fixed)
Total (Random)
n/n1/n2 OR [95% CI] p-value Weight
319/159/160 0.53 [0.34, 0.84] <0.01 41.4
0.50 [0.31, 0.79] 0.003 40.5
169/88/81 0.89 [0.45, 1.79] 0.86 18.1
0.57 [0.42, 0.76] 100.0
0.57 [0.42, 0.77]
330/157/173
Favours EGFRI
+chemotherapy
Favours bevacizumab
+chemotherapy Heterogeneity: Chi
2=2.05, df=2, (p=0.36), I2=3%, Tau2=0
0.1 1 10
Fig. 2. Forest plot showing meta-analysis results for (A) objective response rate, (B) relative difference in objective response rates (RAS
wild-type population). Weight is relative weight (%) from the fixed-effect model. p-value is two sided. CI, confidence interval; EGFRI,
epidermal growth factor receptor inhibitor; N, total study size, n, total number evaluable; n1, number evaluable in the EGFRI arm; n2,
number evaluable in the bevacizumab arm; OR, odds ratio, EGFRI þ chemotherapy/bevacizumab þ chemotherapy; RD, risk difference,
bevacizumab þ chemotherapy (%) e EGFRI þ chemotherapy (%).
V. Heinemann et al. / European Journal of Cancer 67 (2016) 11e2016(95% CI) for EGFRIs þ chemotherapy versus
bevacizumab þ chemotherapy was 0.93 (0.57, 1.51),
suggesting no difference between treatments.
3.2. Safety
A meta-analysis of safety was not possible because
comparable RAS WT data were not available for all
three studies. Grade 3/4 AE data were reported for the
KRAS exon 2 WT population in CALGB/SWOG 80405
(Supplemental Table A1A) [13]. Grade 3 rash (7%
versus 0%) and grade 3 diarrhoea (11% versus 8%)
were more common for cetuximab versus bevacizumab,
respectively. Grade 3 neuropathy (14% versus 12%),
hypertension (7% versus 1%) and gastrointestinal events
(2% versus 0.5%) were more common for bevacizumab
versus cetuximab, respectively. There were 10 grade 5
AEs (bevacizumab nZ 7 [1%], cetuximab nZ 3 [0.5%]).AEs were also reported for the KRAS exon 2 WT
population in FIRE-3 (Supplemental Table A1B) [14].
Of the grade 3/4 AEs with a 2% difference in incidence
between treatments, skin reactions (26% versus 2%),
haematotoxicity (25% versus 21%), acneiform rash (17%
versus 0%), hypokalaemia (7% versus 3%), desquama-
tion (7% versus 0.7%), paronychia (6% versus 0%),
hypomagnesaemia (4% versus 0.7%), infusion-related
allergic reaction (4% versus 0%), and hand-foot syn-
drome (3% versus 0.7%) were more common for cetux-
imab versus bevacizumab, respectively. Diarrhoea (14%
versus 11%), pain (7% versus 5%) and nausea (5% versus
3%) were more common for bevacizumab versus
cetuximab, respectively. There were eight grade 5 AEs
(affecting five patients [2%]) all in the bevacizumab
group.
PEAK [17] was the only trial to report AEs in theRAS
WT population. Of the grade 3/4 AEs with a 2%
V. Heinemann et al. / European Journal of Cancer 67 (2016) 11e20 17difference in incidence between treatments, skin disorders
(34% versus 1%), fatigue (12% versus 10%), hypo-
magnesaemia (8% versus 0%), mucosal inflammation (7%
versus 3%), stomatitis (7% versus 0%), dehydration (6%
versus 1%), decreased appetite (6% versus 0%), and
paronychia (2% versus 0%) were more common for
panitumumab versus bevacizumab, respectively. Hyper-
tension (8% versus 0%) and dysaesthesia (3% versus 0%)
were more common for bevacizumab versus pan-
itumumab, respectively. Eleven patients experienced
grade 5 AEs (panitumumab n Z 4 [5%], bevacizumab
nZ 7 [9%]).
In general, skin toxicities and hypomagnesaemia were
more common with EGFRIs, whereas nausea and
hypertension were more common with bevacizumab.4. Discussion
Although there was heterogeneity between trials, the overall
results of this study-level meta-analysis are supportive of a
potential benefit for first-line EGFRI þ chemotherapy
versus bevacizumab þ chemotherapy with respect to OS,
ORRandETS.However,most patients withmCRC receive
several lines of treatment, all of which may impact OS, and
currently second- and third-line therapy use is not always
reported. It has been argued that the apparent disconnect
between PFS and OSmay be due to potential imbalances in
the use of subsequent therapy. However, a recent analysis
indicated that second- or third-line therapies did not explain
the superior survival observed in the cetuximab arm of
FIRE-3 [21]. In PEAK and FIRE-3, the proportions of
patients crossing over to EGFRI (38% [17] and 41% [14])- or
bevacizumab (40% [17] and 47% [14])-containing regimens,
respectively, appears similar between arms, as was subse-
quent chemotherapy use. However, the largest of the three
trials (CALGB/SWOG 80405) has reported no data on the
incidence/type of subsequent therapy use. Therefore, a
potential imbalance in this study cannot be discounted.
Independent, centrally reviewed response data were only
available for inclusion from the FIRE-3 trial [16].
There have been two other recent meta-analyses
evaluating EGFRI treatment in mCRC [22,23]. The
first demonstrated the benefits of EGFRI versus no
EGFRI treatment in patients with RAS WT mCRC
receiving first- to third-line therapy and showed that
patients with RAS mutations beyond KRAS exon 2 had
outcomes indistinguishable from patients with KRAS
exon 2 mutant tumours [22]. The second meta-analysis,
which included the same three trials as the present study,
demonstrated improved ORR and OS with first-line
EGFRI versus bevacizumab in patients with RAS WT
mCRC [23]. The present meta-analysis adds to this by
including updated ORR and OS data from these studies
and by looking at resection rates as well as the new end-
point: ETS. Exploratory analyses have shown ETS and
also depth of response (DpR) to influence long-termoutcomes in patients with mCRC [24e28] and a meta-
analysis was considered relevant to evaluate any treat-
ment differences with respect to these new end-points.
Although ETS data were only available from PEAK [20]
and FIRE-3 [16], a meta-analysis was undertaken with
results favouring EGFRIs versus bevacizumab. Unfor-
tunately, a meta-analysis of DpR was not possible due
to the nature of how these data are reported. Nonethe-
less, data from the individual trials reported significantly
higher median percentage DpR for EGFRIs versus
VEGFI (Table 2) [20,29]. Given the apparent differences
in ORR and ETS, it was of interest to perform a meta-
analysis of resection rates in these trials. Resection data
for the RAS WT population were only available for
PEAK [30] and FIRE-3 (previously unpublished) and
rates were similar between arms.
The current meta-analysis also assessed the impact of
EGFRIs versus VEGFI in patients with KRAS exon 2
WT/‘other’ RAS mutant mCRC. Patients with these less
common KRAS and NRAS mutations do not benefit
from EGFRIs, and the effects of these mutations appear
similar to those seen in KRAS exon 2 mutant mCRC
[31,32]. The apparent lack of benefit for bevacizumab
relative to the comparator EGFRI in patients with
KRAS exon 2 WT/‘other’ RAS mutant mCRC is
unexpected, but the small number of patients in this
subgroup (n Z 221) may limit interpretation of these
data. Furthermore, these analyses may be complicated
by the fact that some patients received FOLFIRI-based
chemotherapy and a detrimental effect of RAS
mutations in patients receiving EGFRIs þ FOLFIRI
has not been reported. Nonetheless, the effect of any less
common RAS mutations cannot be determined in this
analysis, and additional biomarker research from large
bevacizumab studies would be of interest.
More research is presently being performed to define
the optimum first-line treatment in patients with RAS
WT mCRC. The ongoing Japanese phase III PARA-
DIGM study (NCT02394795) will prospectively
compare the efficacy/safety of first-line mFOLFOX6
plus either panitumumab or bevacizumab in patients
with RAS WT mCRC [33] and should confirm if
EGFRIs are associated with an OS benefit in these
patients. An associated study (NCT02394834) will
investigate the relationship between OS and potential
predictive biomarkers of efficacy/safety using tumour
tissue samples from patients in PARADIGM. The
impact of possible biomarkers in circulating tumour
DNA will also be assessed. Results from both trials are
awaited with interest.
Biological rationales for the improved OS observed
for first-line EGFRI versus bevacizumab have been
proposed, which may support use of first-line EGFRI
followed by VEGFI in patients with RAS WT mCRC.
Based on the available data, it appears that resistance to
EGFRIs may result in biological changes permitting
tumours to retain sensitivity to subsequent therapy,
V. Heinemann et al. / European Journal of Cancer 67 (2016) 11e2018whereas resistance to VEGFIs may also result in resis-
tance to EGFRIs [34]. These hypotheses require testing
in prospectively designed trials. Although the available
clinical trial data presently support the EGFRI
/ VEGFI sequence, none of these trials were actually
designed to assess sequencing. Therefore, there is a need
for randomised, prospective trials to define the optimum
sequence of biological therapy in mCRC. The phase III,
randomised STRATEGIC-1 trial (NCT01910610) will
compare two different strategies: first-line treatment
with FOLFIRI-cetuximab, followed by oxaliplatin-
based chemotherapy with bevacizumab versus first-line
OPTIMOX-bevacizumab, followed by irinotecan-based
chemotherapy with bevacizumab, followed by
EGFRI  irinotecan.
Also, potential differences in safety and treatment
scheduling may influence patient preferences when
choosing first-line treatment. The EGFRIs and
bevacizumab have different side-effect profiles; in general,
skin toxicities and hypomagnesaemia are more common
with EGFRIs, whereas nausea and hypertension occur
more frequently with bevacizumab. Data from the phase
III ASPECCT trial suggest similar efficacy for the
EGFRIs panitumumab and cetuximab, although there
were small differences in the incidence of certain grade 3/4
AEs and in treatment scheduling (2-weekly versus weekly)
[35].
We acknowledge several limitations to the present
meta-analysis: only three head-to-head trials were
available for inclusion and study-level rather than
patient-level data were utilised. With regard to the
CALGB study, it was necessary to utilise congress
abstracts rather than full publications. Notably, the
preliminary report from CALGB only had RAS data
available for 55% of patients. There were also differ-
ences in methodology, outcome assessment and patient
populations between trials that may have impacted on
the meta-analysis findings. It was assumed that the ef-
ficacy of FOLFOX and FOLFIRI was the same [6,7],
although some differences were apparent in the OS/PFS
sensitivity analyses (Supplemental Figs. A2 and A3). It
was also assumed that subsequent therapy use was
similar and balanced between arms/trials. Unfortu-
nately, there were insufficient patient numbers to eval-
uate the impact of individual RAS mutations on
efficacy, although it was assumed that each mutation
had the same effect.
In summary, chemotherapy plus EGFRIs or
bevacizumab are effective first-line treatments for
patients with mCRC. The present meta-analysis as
well results from two of the three individual studies
favour EGFRIs þ chemotherapy versus
bevacizumab þ chemotherapy for some efficacy
outcomes in patients with RAS WT tumours. A
meta-analysis of the relative safety of these combi-
nations is awaited, and an independent patient-level
meta-analysis of efficacy would also be useful. Thecomparative efficacy and safety of the available
first-line options need to be carefully considered as
part of the overall treatment strategy of patients with
RAS WT mCRC.
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